[{"data":1,"prerenderedAt":29},["ShallowReactive",2],{"$f0OPPH5sQQekME0wATcSLNPVuwe9dO63RZ3-anOFBLuw":3},{"code":4,"show":5,"msg":6,"data":7,"status":28},1,0,"",{"info":8,"next":16,"prev":21,"others":25},{"cate_name":9,"id":10,"cid":4,"title":11,"desc":12,"image":13,"content":14,"is_show":4,"home_recommend":4,"publish_at":15},"科技",3,"First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical","https://api-scibrunch.hellokoma.com/uploads/images/20260416/202604161535589162c2350.jpg","\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch Therapeutics\u003C/span> \u003Cspan style=\"font-family: Arial;\">announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical University Cancer Hospital as the two leading sites, has been successfully initiated at Harbin Medical University Cancer Hospital. The first patient was dosed on January 8, 2026, marking a key milestone in the clinical development of SPR1020 and bringing new therapeutic hope to patients.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This is a multicenter, open-label study evaluating SPR1020 in adult patients with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of SPR1020 as a monotherapy. The clinical trial was approved by the National Medical Products Administration (NMPA) in December 2025.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">SPR1020 is a highly selective PARP1 inhibitor with significant advantages in potent brain penetration and high target selectivity. Preclinical studies demonstrate that SPR1020 acts precisely on the PARP1 target, reducing the risk of hematologic toxicity while maintaining efficacy, showing strong potential to become a best-in-class innovative therapy.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch2>\u003Cstrong>About SPR1020\u003C/strong>\u003C/h2>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">SPR1020 is an oral, highly selective, brain-penetrating small-molecule PARP1 inhibitor that is not a substrate for P-glycoprotein (P-gp). Preclinical studies show its excellent performance in selectivity and blood-brain barrier penetration, promising new treatment options for areas with unmet medical needs.\u003C/span>\u003C/p>",1775712313,{"publish_time":17,"id":18,"title":19,"publish_at":20},"2026-04-14",4,"SciBrunch Therapeutics Completes Over  35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent Rounds",1776149657,{"publish_time":22,"id":4,"title":23,"publish_at":24},"2026-04-09","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs",1775712312,[26,27],{"publish_time":17,"id":18,"title":19,"publish_at":20},{"publish_time":22,"id":4,"title":23,"publish_at":24},200,1776763000811]